Tag:

It's no secret that pharma salespeople are barred at the doors of many doctors' offices. Those doors have been closing one by one for several years…barriers are rising at a bad time for drugmakers intent on launching new products to make up for patent-cliff losses. Just as doors are closing, there's been a renaissance in drug approvals, with the FDA blessing record numbers of meds in the past few years…pharma marketers have adopted workarounds--such as digital detailing--face-to-face meetings are still the cornerstone of new drug launches.

Because of the consolidation among generics companies over the last several years, the companies are running out of acquisition targets and as a result, specialty pharma firms are now in the M&A spotlight as acquisitive drugmakers search for new ways to fuel growth,.. 'We think some of the most attractive areas are in the niches. Areas like controlled release, topical or injectable generics.' Potential targets include Impax Laboratories, Akorn Pharmaceuticals and Sagent Pharmaceuticals Inc...